Posted by Michael Wonder on 04 Dec 2020
BioCryst announces FDA approval of Orladeyo (berotralstat), first oral, once-daily therapy to prevent attacks in hereditary angioedema patients
3 December 2020 - Significant and sustained reduction in HAE attacks.
BioCryst Pharmaceuticals today announced that the U.S. FDA has approved oral, once-daily Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and paediatric patients 12 years and older.
